We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Comparison of the Eradication Rate of Second-Line Treatment According to the Type of First-Line Therapies in Helicobacter pylori.
- Authors
Dongwoo Kim; Sung Woo Jung; Jeong Hun Park; Jung Wan Choe; Seung Young Kim; Jong Jin Hyun; Ja Seol Koo; Hyung Jun Yim; Sang Woo Lee
- Abstract
Background/Aims Various therapies have been tried to overcome the antibiotics resistance of Helicobacter pylori. However, little is known about the results of second-line treatment of these first-line therapies. We compared the eradication rates of second-line treatment according to first-line therapy. Methods We analyzed 1,141 patients who have been treated for H. pylori infection from January 2014 to December 2018 in our hospital retrospectively. Treatment regimen was defined as follows; triple therapy-proton pump inhibitor (PPI), amoxicillin and clarithromycin for 14 days; concomitant therapy-PPI, amoxicillin, clarithromycin and metronidazole for 10 days; sequential therapy-PPI, amoxicillin for 5 days, followed by PPI, clarithromycin, metronidazole for 5 days; hybrid therapy-PPI, amoxicillin for 5 days, followed by PPI, amoxicillin, clarithromycin, metronidazole for 5 days; and PBMT therapy-PPI, bismuth, metronidazole, tetracycline for 14 days. All the patients took PBMT therapy for second- line treatment. Results The eradication rate of first-line treatment was 88.4% (1,009/1,141). The eradication rate was 84.0% (379/4,515) for triple therapy, 92.7% (537/498) for concomitant therapy, 87.3% (103/118) for sequential therapy, 82.9% (29/35) for hybrid therapy respectively. Concomitant therapy had a significantly high eradication rate than the other therapies (92.7%, p<0.001). 132 patients underwent second-line treatment of H. pylori with PBMT regimen. The eradication rate of second-line treatment were 84.8% (112/132). The eradication rate according to the type of first-line treatment is as follows. The 83.3% (60/72) for triple therapy, 84.6% (33/39) for concomitant therapy, 73.3% (11/15) for sequential therapy and 83.3% (5/6) for hybrid therapy (p=0.795) (Fig. 1). There was no significant difference in eradication rate according to first-line therapy. Conclusions There was no significant difference in eradication rate of second-line PBMT therapy according to first-line therapy.
- Subjects
HELICOBACTER pylori; DRUG resistance in bacteria; AMOXICILLIN; CLARITHROMYCIN; TETRACYCLINES
- Publication
Gut & Liver, 2019, Vol 13, Issue 6(suppl. 1), p144
- ISSN
1976-2283
- Publication type
Article